JP2023533682A5 - - Google Patents
Info
- Publication number
- JP2023533682A5 JP2023533682A5 JP2022579955A JP2022579955A JP2023533682A5 JP 2023533682 A5 JP2023533682 A5 JP 2023533682A5 JP 2022579955 A JP2022579955 A JP 2022579955A JP 2022579955 A JP2022579955 A JP 2022579955A JP 2023533682 A5 JP2023533682 A5 JP 2023533682A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- antibody
- antigen
- binding fragment
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043613P | 2020-06-24 | 2020-06-24 | |
| US63/043,613 | 2020-06-24 | ||
| PCT/US2021/031141 WO2021262329A1 (en) | 2020-06-24 | 2021-05-06 | Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533682A JP2023533682A (ja) | 2023-08-04 |
| JP2023533682A5 true JP2023533682A5 (enExample) | 2025-01-14 |
Family
ID=76181259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579955A Pending JP2023533682A (ja) | 2020-06-24 | 2021-05-06 | 補体関連病態の処置用抗ｃ５抗体の皮下（ｓｃ）投与 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4171737A1 (enExample) |
| JP (1) | JP2023533682A (enExample) |
| CN (1) | CN116194478A (enExample) |
| CA (1) | CA3173011A1 (enExample) |
| WO (1) | WO2021262329A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3873602B1 (en) | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| EP4281472A1 (en) * | 2021-01-22 | 2023-11-29 | Alexion Pharmaceuticals, Inc. | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
| TW202346339A (zh) * | 2022-04-04 | 2023-12-01 | 瑞士商赫孚孟拉羅股份公司 | 藉由使用抗ｃ５抗體克羅伐單抗之治療或預防格林－巴利症候群之劑量及投予方案 |
| WO2024229000A1 (en) * | 2023-05-02 | 2024-11-07 | Alexion Pharmaceuticals, Inc. | Pediatric dosage and administration of anti-c5 antibodies for treatment of complement disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| WO2014099546A1 (en) | 2012-12-19 | 2014-06-26 | Promerus, Llc | Process for the preparation of high purity norbornene alkanols and derivatives thereof |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| US20170182242A1 (en) * | 2015-12-27 | 2017-06-29 | Abbvie Inc. | Wearable Automatic Injection Device and Related Methods of Use |
| EP3402816A1 (en) * | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| EP3873602B1 (en) * | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
-
2021
- 2021-05-06 CA CA3173011A patent/CA3173011A1/en active Pending
- 2021-05-06 CN CN202180051583.9A patent/CN116194478A/zh active Pending
- 2021-05-06 EP EP21728735.8A patent/EP4171737A1/en active Pending
- 2021-05-06 JP JP2022579955A patent/JP2023533682A/ja active Pending
- 2021-05-06 WO PCT/US2021/031141 patent/WO2021262329A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023533682A5 (enExample) | ||
| US12528859B2 (en) | Single domain serum albumin binding protein | |
| JP2022512632A5 (enExample) | ||
| JP7489978B2 (ja) | 抗ＦｃＲｎ抗体を用いたグレーブス眼症の治療方法 | |
| JP2021525718A5 (enExample) | ||
| JP2023533030A5 (enExample) | ||
| JP2021526534A5 (enExample) | ||
| WO2023023345A2 (en) | Methods of using activin receptor type ii signaling inhibitors | |
| EP3554543A2 (en) | Stable aqueous anti-c5 antibody composition | |
| NO20170737A1 (no) | Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff | |
| TW202417482A (zh) | 治療補體介導疾病的方法 | |
| JP7722991B2 (ja) | 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法 | |
| JP2023507795A5 (enExample) | ||
| KR20250115370A (ko) | Fviii 모방 이중특이적 항체의 주 1회 투여 방법 | |
| JP2023539047A5 (enExample) | ||
| JP2018502862A (ja) | 持続型ｅｐｏ製剤を用いた貧血治療方法 | |
| KR102868672B1 (ko) | Fviii 모방 이중특이적 항체를 2주마다 1회 투여하는 방법 | |
| KR102839278B1 (ko) | Fviii 모방 이중특이적 항체의 월 1회 투여 방법 | |
| JP7739537B2 (ja) | Ｆｖｉｉｉ模倣二重特異性抗体を２ヶ月に１回投与する方法 | |
| RU2021125057A (ru) | ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС) | |
| JP2023507852A5 (enExample) | ||
| RU2024117500A (ru) | Дозы и введение антител против c5 для лечения атипичного гемолитико-уремического синдрома (агус) | |
| CN118021955A (zh) | 用于治疗il-17a介导的疾病或病症的方法和组合物 | |
| AU2024326775A1 (en) | High concentration formulations for anti-insulin receptor antibody and uses thereof | |
| AU2023276914A1 (en) | Methods and compositions for treatment of thyroid eye disease |